Comparison of Absorbed Dose Coefficients and Absorbed Doses for Several Prostate-Specific Compounds
| 124I-PSMA | 123I-MIP-1072 | 123I-MIP-1095 | Pentixafor | DOTATOC | DOTATATE | 18F-FDG | PSMA-IT | ||
| Target organ | Unit | Zechmann (33) | Barrett (36) | Barrett (36) | Herrmann (25) | Sandstrom (34) | Sandstrom (34) | ICRP 106 (35) | This work |
| Kidneys | mSv/MBq | 1.39E+00 | 5.4E–02 | 1.10E–2 | 3.50E–02 | 8.20E–02 | 9.30E–02 | 1.70E–02 | 2.20E–01 |
| Liver | mSv/MBq | 1.66E–00 | 2.4E–02 | 5.8E–2 | 1.75E–02 | 4.10E–02 | 5.00E–02 | 2.10E–02 | 4.31E–02 |
| Spleen | mSv/MBq | 7.7E–01 | 2.3E–2 | 4.7E–2 | 5.38E–02 | 1.08E–01 | 1.09E–01 | 1.10E–02 | 6.34E–02 |
| Urinary bladder wall | mSv/MBq | 5.7E–01 | 9.2E–2 | 2.1E–2 | 8.14E–02 | 1.19E–01 | 9.80E–02 | 1.30E–01 | 6.74E–02 |
| Effective dose coefficient | mSv/MBq | 5.8E–01 | 2.5E–2 | 3.2E–2 | 1.56E–02 | 2.10E–02 | 2.10E–02 | 1.90E–02 | 1.99E–02 |
| Typical injected activity | MBq | 67 | 370 | 370 | 150 | 185 | 150 | 370 | 150 |
| Effective dose | mSv | 38.9 | 9.3 | 11.8 | 2.3 | 3.9 | 3.2 | 7.0 | 3.0 |